Mepolizumab
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Mepolizumab: From Severe Eosinophilic Asthma to Immune Thrombocytopenia
One-Sentence Summary
Mepolizumab is a humanized monoclonal antibody targeting interleukin-5 (IL-5), clinically used for severe eosinophilic asthma and other eosinophil-driven diseases. The TxGNN model predicts it may be effective for Thrombocytopenia due to Immune Destruction, but this direction is currently supported only by 1 case-level publication, with no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not confirmed in this evidence pack (drug is unmarketed in this jurisdiction; no license text available) |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 99.66% |
| Evidence Level | L4 |
| Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap in this evidence pack). Based on general known information, mepolizumab is an anti-IL-5 monoclonal antibody that depletes eosinophils by blocking IL-5-mediated survival and activation signaling; it is used in eosinophil-driven diseases such as severe eosinophilic asthma and related hypereosinophilic conditions.
The single supporting literature item in this pack describes a case in which mepolizumab resolved a steroid-resistant, hypereosinophilic condition with concomitant improvement of a thrombotic microangiopathy — suggesting a possible mechanistic overlap between eosinophil-driven inflammation and immune-mediated platelet destruction/consumption. This provides a plausible biological rationale for the TxGNN prediction, but it is a single case observation rather than a validated causal mechanism, so the linkage should be considered exploratory.
Formal confirmation of the drug's original approved indication(s) and MOA (via DrugBank/regulatory label) is required before this mechanistic rationale can be treated as established evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28648630 | 2018 | Case report | Blood Cells, Molecules & Diseases | Mepolizumab resolved a steroid-resistant hypereosinophilic diathesis, with concomitant amelioration of a mixed thrombotic microangiopathy, in a patient with atypical hemolytic uremic syndrome |
Norway Market Information
This product is currently not marketed and has no license records available in this evidence pack (0 authorizations).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence supporting this indication consists of a single case report with no registered clinical trials, and core drug-level data (original approved indication, MOA, TFDA/label warnings) are marked as blocking or high-severity data gaps. The mechanistic rationale is plausible but not yet substantiated.
To proceed, the following is needed:
- TFDA/regulatory label data (warnings, contraindications) — currently a Blocking gap (DG001)
- Confirmed mechanism of action from DrugBank — currently a High-severity gap (DG002)
- Confirmed original approved indication(s) for the drug
- Additional clinical evidence (trials or observational studies) specifically evaluating anti-IL-5 therapy in immune thrombocytopenia, beyond the single case report currently available
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.